* WISKY: AI-Powered Retinal Disease Diagnostic Solution WISKY is an advanced solution that performs real-time analysis of images captured by fundus cameras to detect age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. It serves as a vital tool for internal medicine clinics, f...
Manufactured by
ARK INC.
South Korea
ARK INC. is a company dedicated to improving the quality of life for all people by developing early disease detection solutions based on artificial intelligence (AI). As a subsidiary of Pusan National University Hospital, ARK leverages trustworthy national university hospital data and a standardized clinical research system to develop highly accurate AI diagnostic algorithms. ⸻ Flagship Product – WISKY: AI-based Ophthalmic Disease Screening Solution WISKY, the flagship product of ARK, is an AI-powered retinal disease screening platform. Using a single fundus image, WISKY can simultaneously detect three major causes of blindness in real time: • Diabetic Retinopathy • Age-related Macular Degeneration (AMD) • Glaucoma Recognized for its diagnostic accuracy and ease of use, WISKY has been designated as an Innovative Medical Device in Korea. This technology is highly regarded for its market potential, especially amid the rising incidence of retinal diseases due to an aging population and chronic conditions. ⸻ Advanced AI Technology Powered by Big Data • ARK has built a comprehensive dataset of over 500,000 retinal images, which serves as the foundation for a robust and optimized AI training model. • The diagnostic system is user-friendly, allowing even non-specialist medical staff to operate it easily. • This makes it particularly suitable for primary care settings, such as community health centers and local clinics. With this technological advantage, ARK is actively expanding into global markets as well as strengthening its domestic presence.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Optain Health
Australia · 2 relevant products
Remidio Innovative Solutions Pvt. Ltd.
India · 5 relevant products
Hangzhou Deepwise & League of PHD Technology Co.,Ltd.
China · 4 relevant products
38 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →11 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 56 closest product alternatives
Optain Health · Australia
AI-enabled Software as a Medical Device (SaMD) that analyzes full-colour retinal images to screen for referable eye diseases and cardiovascular disease risk. The software generates instant risk assessment reports for clinical decision-making and patient care optimization.
Remidio Innovative Solutions Pvt. Ltd. · India
AI-powered screening system for diabetic retinopathy detection using fundus imaging. Enables non-invasive, population-scale vision screening in primary care and community settings to identify patients requiring specialist referral. Combines portable fundus photography with machine learning algorithms for early disease detection and risk stratification.
Optain Health · Australia
An AI-enabled clinical support tool that analyzes full-color retinal images to screen for referable eye diseases and evaluate patient health. The non-invasive solution uses advanced algorithms to provide accurate assessments and standardized care recommendations for providers, patients, and insurers.
53 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products